Corcept (CORT): Every Signal Landed in the Middle Band. That Is the Signal.
Three of Corcept's Cushing's durability defenses cracked in a 90-day window. Lifyorli was approved four months ahead of PDUFA. The balance sheet carries $532M cash and zero debt. Seven committee lenses arrived independently at the same unusual place.
Zero debt, zero covenants, zero maturities
~100% Korlym franchise today
Authorized generic at ~30% WAC discount
Dec 2025 - Feb 2026 window
Corcept Therapeutics spent most of 2025 trading as a high-confidence orphan-drug compounder. Then three of the four principal durability defenses for its flagship Cushing's franchise degraded inside a single 90-day window. The Federal Circuit ruled against Corcept in Teva v. Corcept, eroding composition-of-matter patent protection. The FDA issued a Complete Response Letter on relacorilant for Cushing's, blocking the planned lifecycle extension. And the Q4 2025 specialty pharmacy transition produced a 24-percentage-point gap between scripts (+61%) and tablet volume (+37%), leaving roughly $65-90M in prescriptions undispensed.
Against that sits a different company. On 2026-03-25 the FDA approved Lifyorli (relacorilant for platinum-resistant ovarian cancer) four months ahead of its July PDUFA, with 7-year orphan exclusivity and a +4.1 month overall survival benefit in the all-comer label. The balance sheet carries $532M in cash and investments, zero debt, zero covenants, and $142M of FY2025 free cash flow. A sitting director bought $3.3M of stock in the open market on 2026-03-17, eight days before the approval drove the price above $50.
Seven committee lenses ran the setup through structured discourse. Something unusual happened: every single signal landed in the cautious middle band. REVENUE_DURABILITY FRAGILE. COMPETITIVE_POSITION DEFENSIBLE-at-boundary. NARRATIVE_REALITY_GAP GAP_BEARISH. EXPECTATIONS_PRICED UNDERPRICED. ACCOUNTING_INTEGRITY QUESTIONABLE. GOVERNANCE_ALIGNMENT MIXED. TAIL_RISK_SEVERITY ELEVATED. None of those readings are alarming in isolation. Their simultaneity is the story.
Want the full 7-lens analysis with signal assessments and model debates?
Opus + Sonnet ensemble. 7 lenses. 13 signals. 8 debates. Full evidence citations.
Signal Assessments
Seven lenses. Thirteen signals. Every assessment landed in the unusual/cautious middle bucket. The density is the diagnostic.
Three principal Korlym defenses weakened in 90 days: Teva Federal Circuit loss, relacorilant Cushing's CRL, and a Q4 specialty pharmacy miss that left $65-90M undispensed.
Three active regulatory fires plus multiple pending FDA decisions across a franchise where 100% of current revenue sits on a single CMS-regulated orphan drug.
Aggregate DEFENSIBLE rests on Lifyorli 7-year orphan exclusivity and SGRA platform validation. Revenue-generating Korlym franchise is CONTESTED at the indication level.
Market appears to have credited Lifyorli ~$200M when comparable specialty-oncology first-approvals command $500M-$2B. Pipeline option value near-zero in the multiple.
EV/sales of 3.6-4.0x on $900M-$1B FY26 guide. Analyst-constructed bear weight 20-25% against a market-implied ~45%. MEDIUM confidence on the calibration.
$33.2M tax benefit reduced visible earnings decline from -59% pre-tax to -29% net. $245M 'buyback' includes $72.9M of tax-withholding on equity comp. OCF/NI 1.42 remains clean.
Revenue-only 2026 CSM plus CFO/endocrinology-president 10b5-1 adoptions 18-22 days pre-CRL. Offset by Director Baker's $3.3M open-market buy during personal litigation.
$532M cash, zero debt, $142M FCF, 4-5 year runway under stress. Traditional covenant/maturity framework produces degenerate answers; the balance sheet cannot break in any conventional sense.
SG&A +60% on +13% revenue, salesforce scaled 2.5x front-running the subsequently-CRL'd asset. Buybacks at $44 vs stock now $33-40. Zero M&A, zero dividends, zero exotic engineering.
Two concentrated shared assumptions (Lifyorli Year 1 at $50M+, SGRA class safety) each move 3+ signals if broken. Joint fragility 12-18% over 18 months.
Compound-failure scenarios at 7-11% joint probability produce 40-70% equity compression. Company viability not threatened by any scenario short of SGRA class-wide hold.
Signal-level disagreement is real. Five frame-level gaps identified where implicit shared framing was not stress-tested. Balance-sheet-as-acquisition-attractor was neither analyst's original construction.
Key Findings
Three Durability Defenses Cracked in 90 Days
The Teva Federal Circuit loss in February 2026 weakened composition-of-matter patent protection nominally running to 2037. The Cushing's relacorilant CRL on 2025-12-30 blocked the planned lifecycle extension. The Q4 2025 specialty pharmacy transition produced a 24-percentage-point gap between scripts and tablet volume, an approximate $65-90M channel miss. A fourth defense (the authorized generic at ~30% WAC discount) captures volume but compresses per-patient economics. Three of four principal defenses degraded inside a single 90-day window. The FRAGILE reading is a level-maintenance assessment of $761M revenue durability, not an existence reading.
The Balance Sheet Cannot Break in Any Conventional Sense
$532M cash and investments, with zero debt, covenants, maturities, or rating exposure. FY25 free cash flow of $142M despite a 28% decline. The traditional Stress Scanner framework (covenant headroom, refinancing risk, maturity wall) produces degenerate answers because none of those exist. Reframed around cash runway, the committee modeled Korlym -25% plus Medicaid compression plus sticky SG&A plus slow Lifyorli ramp and arrived at 4-5 years of runway. A compound-failure scenario (Korlym -50% plus Lifyorli delayed plus Phase 3 R&D acceleration) compresses runway to roughly 24 months at 10-18% probability. RESILIENT is a strong reading of a strong balance sheet.
Dual Execution Risk Is the Tail No Individual Lens Owns
Black Swan Beacon constructed six compound scenarios with lens-grounded evidence. The highest probability-times-severity tail is Scenario B: Dual Execution Failure. Korlym erosion accelerates (scripts-vs-tablets gap persists, third-party ANDA files) at the same time Lifyorli's Q2/Q3 2026 launch stumbles (first-line SAE rate remains 35%, discontinuation at 9%, sub-$30M first-year run rate). Both vectors share a commercial leadership team and a revenue-only compensation design that incentivizes top-line growth over execution quality. Probability 12-18% over 18 months, SEVERE severity, cascades across REVENUE_DURABILITY, CAPITAL_DEPLOYMENT, and NARRATIVE_REALITY_GAP simultaneously.
Directors Retain, Officers Monetize, and One Director Bought $3.3M
Directors hold roughly 6.3M shares collectively (Belanoff 2.9M, Baker 1.1M, Mahoney 1.2M, Wilson 1.1M). Operating officers hold de minimis direct shares: Guyer 2K, Maduck 9K, Mokari 15K. CFO Mokari adopted a 200K-share 10b5-1 plan on 2025-12-12; President of Endocrinology Maduck adopted a 600K-share plan on 2025-12-08. The Cushing's CRL landed on 2025-12-30, 18 and 22 days after plan adoption. Cooling-off compliance is satisfied. No Form 4 cluster-sell preceded the CRL. MNPI status at adoption is unresolvable from public record. Director Baker's $3.3M open-market purchase on 2026-03-17, eight days before Lifyorli approval, runs in the opposite direction. Baker is also a defendant in the Ritchie derivative suit. The structural asymmetry is the signal; no single transaction resolves it.
Single-Mechanism Platform Risk Across Four Programs
All four pipeline programs (relacorilant, dazucorilant, miricorilant, nenocorilant) antagonize the glucocorticoid receptor through the same SGRA mechanism. A class-level safety signal such as ALT elevation above 5x ULN across two or more trials, or CYP-related hepatotoxicity, would cascade non-linearly across Cushing's, platinum-resistant ovarian cancer, ALS, and MASH simultaneously. Black Swan Beacon placed this at 4-11% probability over 18 months with MATERIAL-to-SEVERE severity. Modern FDA surveillance dampens the withdrawal precedent (Rezulin, Vioxx) in favor of REMS and label updates, but the mechanism concentration is the tail no ordinary lens owns. EXPOSED is the right single-word assessment of the platform dependency structure.
Where Models Disagreed
FRAGILE or CONDITIONAL? The Level-Maintenance Reading
Adopted
FRAGILE. Three principal durability defenses have already changed inside a 90-day window. The definition triggers when material revenue depends on conditions that could realistically change; the conditions have already changed.
Withdrawn
CONDITIONAL (defenses concentrated but intact). Withdrawn after accepting the level-maintenance reading: current $761M durability, not existence. Natural single-round convergence.
GAP_BEARISH or GAP_BULLISH? Which Gap Is Operative?
Adopted
GAP_BEARISH as the operative market-pricing signal. Lifyorli appears credited ~$200M against $500M-$2B comparables. Pipeline option value near-zero in the multiple.
Withdrawn
GAP_BULLISH on the management side. Withdrawn as the signal label but retained as a qualitative credibility discount on forward forecasts: $3-5B relacorilant peak maintained post-CRL, "diversified oncology company" while 2026 remains near-100% Cushing's.
DEFENSIBLE or CONTESTED? The Aggregation Question
Converged on DEFENSIBLE at the lower boundary with LOW confidence. Aggregate rests on forward-looking Lifyorli plus SGRA platform validation; per-indication, the revenue-generating Korlym franchise is CONTESTED today. Medium-term trajectory likely passes through CONTESTED in 2028 before potential pipeline-driven recovery. A reader weighting revenue-generating-moat over forward-option-moat would reasonably land on CONTESTED today.
TAIL_RISK_SEVERITY: Company Survival vs Thesis Survival
Adopted
ELEVATED as the honest middle. Thesis does not survive compound stress at 7-11% joint probability. Company viability is not threatened short of an SGRA class-wide safety hold plus further adverse facts.
Withdrawn
SEVERE (Catastrophist initial position, citing compound correlation). Withdrawn as company survival is guaranteed by balance sheet, Lifyorli orphan label, and residual mifepristone franchise. Thesis invalidation is the operative tail, not company failure.
Cross-Lens Reinforcements
Gravy Gauge (durability) and Moat Mapper (competitive position) independently identify the February 2026 ruling as the primary hit to Korlym franchise durability. 50-80% of branded revenue at risk on third-party ANDA entry over 12-36 months.
Gravy Gauge, Stress Scanner, and Moat Mapper all cite $532M cash + zero debt + $142M FCF as the reason FRAGILE/CONTESTED/MIXED middle-band readings do not translate into going-concern risk. 4-5 year runway under stress.
Myth Meter, Insider Investigator, and Stress Scanner independently identify the $3.3M open-market purchase as a substantive alignment signal, partially discounted for litigation optics. All three note the market is not crediting it.
Fugazi Filter and Stress Scanner independently fingerprint the 2026 DEF 14A revenue-only Company Selected Measure as the structural mechanism driving 1,440bps of operating margin compression over two years.
Gravy Gauge and Stress Scanner both treat the Q4 scripts-vs-tablets 24-point gap as a channel execution signal rather than underlying demand weakness. The Q1 2026 10-Q is the first structural test of transitory vs durable.
Fugazi Filter and Insider Investigator both flag the Maduck (12/8/2025) and Mokari (12/12/2025) plan adoptions. Cooling-off compliance satisfied; MNPI-at-adoption unresolvable from public record; no Form 4 cluster-sell preceded the CRL.
What to Watch
Binary across multiple signals. Resubmission path holds DEFENSIBLE, improves FRAGILE trajectory, reduces ELEVATED regulatory exposure. New-trial requirement strands $80-150M of SG&A, deepens FRAGILE, pressures DEFENSIBLE toward CONTESTED.
Single highest-leverage near-term trigger for re-rating. Above $50M annualized by Q4 2026 reinforces DEFENSIBLE, narrows GAP_BEARISH, resolves UNDERPRICED. Below $50M flips the moat and myth meter theses simultaneously.
Any two of four SGRA programs disclosing ALT elevation or shared-mechanism safety findings by mid-2027 would degrade DEFENSIBLE toward ERODING in a single step and activate thesis-killer scenarios. 4-11% probability over 18 months.
First near-term test of the specialty pharmacy transition. Q4 showed a 24-point gap (+61% scripts vs +37% tablets). A gap narrower than 10 points in the May 2026 10-Q would suggest transitory; persistence would confirm structural.
Price-triggered execution at post-CRL lows would escalate MIXED to MISALIGNED in one step and reopen the MNPI-at-adoption question reputationally. Time-based cadence at any price maintains MIXED.
Scenario E (Balance Sheet Inversion) was identified adversarially. Neither analyst originally constructed this frame. $532M cash plus Lifyorli approval plus SGRA platform at a compressed valuation creates acquisition-attractor optics. 8-12% unconditional probability; 30-45% conditional on a dual-execution or regulatory-plus-governance stress.
Higher Scrutiny
Corcept is mid-transition. The fragility is recent rather than structural, and the balance sheet removes going-concern risk, but the density of middle-band signals across seven lenses is the diagnostic. The UNDERPRICED reading is real, and the fact pattern supports a 20-25% bear weight against a market-implied ~45%. But that asymmetry only works if the calibration holds through Q1 2026 data, the April FDA meeting, Lifyorli's first two commercial quarters, and the first Form 4 executions under the new 10b5-1 plans. The number of middle-band readings that could tip on any of those data points argues for deeper investigation, not a committed posture.
Path to More Favorable Assessment
- • April 2026 FDA meeting confirms resubmission path
- • Lifyorli Q3 2026 annualized run rate above $50M with clean label
- • Q1 10-Q scripts-vs-tablets gap narrows below 10 points
- • Director Baker follow-on purchase on any dip
- • 2027 DEF 14A adds EBITDA/operating income/TSR metric
Path to Less Favorable Assessment
- • FDA requires new Phase 3 trial for relacorilant
- • Lifyorli Year 1 run rate below $30M
- • First Form 4 sales under new 10b5-1 plans at price below $40
- • Medicaid short-term accrual exceeds $15M in Q1/Q2 10-Q
- • Third-party mifepristone ANDA files by end-2026
- • Any class-level SGRA safety disclosure
This analysis is for educational purposes only. It is not a recommendation to buy or sell any security.
Public Sources Used
- • Annual Report (10-K) — FY2025
- • Quarterly Reports (10-Q) — Q2, Q3 2025
- • Proxy Statement (DEF 14A) — 2026
- • Current Report (8-K) — Lifyorli FDA Approval (2026-03-25)
- • Current Report (8-K) — Q4 2025 Earnings (2026-02-24)
- • Current Reports (8-K) — 20 filings (May 2024 – March 2026)
- • Form 4 Insider Transactions — 20 filings (Feb-Apr 2026)
- • Form 144 Proposed Sales — 10 filings (Nov 2025 – Apr 2026)
- • Q1-Q4 2025 Earnings Call Transcripts
- • CourtListener Litigation Search — 10 cases (incl. Ritchie derivative C.A. 2022-0102-BWD)
- • Greenhouse Job Postings — 43 listings (commercial buildout signals)
Full Analysis with Signal Breakdowns
Explore the complete 7-lens assessment including debate transcripts, evidence citations, and twelve monitoring triggers for Corcept.
View CORT Analysis